Techguide NewstickerClinical Trial, Open for Enrollment: A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple SclerosisMonday, December 15th, 2008A Multiple Sclerosis clinical trial is now open for enrollment. It is a phase II study aimed at the treatment of poor prognosis Multiple Sclerosis. Diagnostic Criteria for MSMonday, September 22nd, 2008Diagnosing Multiple Sclerosis. Dr. Roberto Bomprezzi goes into detail on the criteria and difficulty in early diagnosis of MS. Functional Electrical Stimulation and Multiple Sclerosis: Seperating Fact from FictionFriday, August 29th, 2008Functional electrical stimulation and Multiple Sclerosos- Get the facts from Brian Hutchinson, PT, MSCS-CEO. Hispanic/Latino NARCOMS ParticipantsThursday, August 7th, 2008North American Research Committee on Multiple Sclerosis summary of Registry participants who have identified themselves as Hispanic or Latino. Monoclonal Antibodies: A New Way to Treat MSWednesday, May 28th, 2008New class of therapy used to combat multiple sclerosis (MS)- Monoclonal antibodies (MABs). |
|